SCHEMBL2444894

SCHEMBL2444894

COc1cccc(-c2cc3c(Cl)ccnc3[nH]2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 1/20 0.64
CDK1 P06493 1/20 0.64
CCNB1 P14635 1/20 0.64
GSK3A P49840 1/20 0.64
GSK3B P49841 1/20 0.64
CDK5 Q00535 1/20 0.64
CDK5R1 Q15078 1/20 0.64
CCNB3 Q8WWL7 1/20 0.64
MAPKAPK2 P49137 1/20 0.58
CSF1R P07333 1/20 0.51
NPY5R Q15761 1/20 0.50
IKBKB O14920 1/20 0.48
CHUK O15111 1/20 0.48
CDC7 O00311 1/20 0.47
PIM1 P11309 1/20 0.47
CDK9 P50750 1/20 0.47
DYRK1A Q13627 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
GCGR P47871 1/20 0.46
MAPK14 Q16539 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31240625 0.88 CCNB2 (0.50) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL31240761 0.88 CCNB2 (0.50) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL31240760 0.88 CCNB2 (0.50) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL31240735 0.84 CCNB2 (0.45) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL31240595 0.82 CDK1 (0.49) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL7495582 0.82 CSF1R (0.59) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL31240593 0.80 CDC7 (0.59) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL16041244 0.80 CDC7 (0.59) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL31240374 0.80 MAOA (0.43) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL31240688 0.80 CDK9 (0.50) CCNB2CDK1CCNB1GSK3BCCNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859581-B2 Azaheterocyclic compounds as kinase inhibitors MERCK PATENT GMBH (DE) 2014-10-14 US disclosed
EP-1874769-B1 NOVEL AZA- HETEROCYCLES SERVING AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-09-14 EP disclosed
US-20080176892-A1 Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene MERCK PATENT GMBH (DE) 2008-07-24 US disclosed
EP-1874769-A1 NOVEL AZA- HETEROCYCLES SERVING AS KINASE INHIBITORS Merck Patent GmbH (DE) 2008-01-09 EP disclosed
WO-2006114180-A1 NOVEL AZA- HETEROCYCLES SERVING AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176892-A1 Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene IGF1R, IGFBP1, ERBB2 CCNB2 693/4885CDK1 99/4885CCNB1 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.